The FDA approved a new drug for diabetes today – Tanzeum (albiglutide), a once per week injectible GLP-1 receptor agonist.
This new drug is for people with type 2 diabetes who require additional help control their blood sugar levels.
The drug is in the drug class GLP-1 receptor agonist class, the same class as current brand name drugs on the market – Victoza, Byetta and Bydureon.
These are all injectible drugs and the newer medication which was approved goes by the brand name Tanzeum (albiglutide) and is manufactured by the pharmaceutical company GlaxoSmithKline.
This drug is the second in the class which has an extended release formulation which makes it a once weekly drug for the treatment of type 2 diabetes.
This class of drugs is known for controlling type 2 diabetes by improving GLP-1 function. A hormone which is defective in people with type 2 diabetes and responsible for first phase insulin response following a meal.
A secondary benefit of this class of drugs is weight loss and increased satiety.
Speak with your doctor to learn more.